Quest Diagnostics beat Q1 estimates with 15.2% revenue growth and lifted its 2025 guidance amid rising volumes and solid ...

Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...

In the recent 13F filings, Pfizer has seen a mix of investment adjustments from 11 institutions, reflecting a divided market ...

We get into the heart of the Q2 earnings season this week, with more than 400 companies on deck to report results, including 109 S&P 500 members. The reporting docket expands beyond the Finance core, ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets.

Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3. StockStory aims to help individual investors beat the market.

On a per-share basis, the New York-based company said it had profit of 52 cents. Earnings, adjusted for amortization costs and restructuring costs, were 92 cents per share.

We think Pfizer’s top line will see growth in the low teens, driven by market share gains for Vyndaqel and Abrysvo.

Pfizer Inc. (NYSE:PFE) currently pays a quarterly dividend of $0.42 per share and has a dividend yield of 5.64%, as of September 18.

With Pfizer’s sales rising in Q2, despite falling sales of Covid-19 products, we think that it may well be the turning point for Pfizer stock .

Pfizer Inc. (NYSE:PFE) Q2 2024 Earnings Conference Call July 30, 2024 10:30 AM ETCompany ParticipantsFrancesca DeMartino – Chief Investor Relations Officer ...